The National Health Care Institute of the Netherlands is more or less a scientific body that does the health technology assessment. It basically advises the minister on adding certain drugs to the formulary and the reimbursement. They assess the drug. They also do a cost-effective analysis based on the price the company provides, and they advise the minister on that. In the end, the minister decides what the maximum reimbursement will be for out-patient drugs.
On May 2nd, 2017. See this statement in context.